STUDY OF CTNNB1 SOMATIC MUTATIONS IN EARLY STAGE ‎ENDOMETRIAL CANCER IN A COHORT OF EGYPTIAN PATIENTS
Zakaria, N., Tayae, E., Nabil, S., Hegazy, N., Mohamed Ali Salem, A. (2024). STUDY OF CTNNB1 SOMATIC MUTATIONS IN EARLY STAGE ‎ENDOMETRIAL CANCER IN A COHORT OF EGYPTIAN PATIENTS. EKB Journal Management System, 6(2), 3-4. doi: 10.21608/alexpo.2024.280641.1819
Nermine ‎ Hossam ELDin Zakaria; Eman Tayae; Samar Nabil; Neamat Hegazy; Asmaa Mostafa Mohamed Ali Salem. "STUDY OF CTNNB1 SOMATIC MUTATIONS IN EARLY STAGE ‎ENDOMETRIAL CANCER IN A COHORT OF EGYPTIAN PATIENTS". EKB Journal Management System, 6, 2, 2024, 3-4. doi: 10.21608/alexpo.2024.280641.1819
Zakaria, N., Tayae, E., Nabil, S., Hegazy, N., Mohamed Ali Salem, A. (2024). 'STUDY OF CTNNB1 SOMATIC MUTATIONS IN EARLY STAGE ‎ENDOMETRIAL CANCER IN A COHORT OF EGYPTIAN PATIENTS', EKB Journal Management System, 6(2), pp. 3-4. doi: 10.21608/alexpo.2024.280641.1819
Zakaria, N., Tayae, E., Nabil, S., Hegazy, N., Mohamed Ali Salem, A. STUDY OF CTNNB1 SOMATIC MUTATIONS IN EARLY STAGE ‎ENDOMETRIAL CANCER IN A COHORT OF EGYPTIAN PATIENTS. EKB Journal Management System, 2024; 6(2): 3-4. doi: 10.21608/alexpo.2024.280641.1819

STUDY OF CTNNB1 SOMATIC MUTATIONS IN EARLY STAGE ‎ENDOMETRIAL CANCER IN A COHORT OF EGYPTIAN PATIENTS

ALEXMED ePosters
Article 1, Volume 6, Issue 2, April 2024, Page 3-4  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.280641.1819
View on SCiNiTO View on SCiNiTO
Authors
Nermine ‎ Hossam ELDin Zakaria1; Eman Tayae2; Samar Nabil3; Neamat Hegazy4; Asmaa Mostafa Mohamed Ali Salem email 5
1Department of Clinical and chemical pathology‎, Faculty of Medicine, Alexandria University
2Clinical and Chemical Pathology Department,Faculty Of Medicine , Alexandria University.
3Department of Pathology, Faculty of Medicine, Alexandria University
4Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University
5Department of Clinical and chemical pathology, ‎Faculty of Medicine, Alexandria University
Abstract
Endometrial cancer is the sixth most prevalent cancer among women and the thirteenth cause of ‎mortality in women worldwide. It is the eighth most prevalent cancer in women in Egypt and ‎the fifteenth cause of mortality in women in Egypt. Endometrioid endometrial carcinoma is the ‎most common type (70%) of endometrial cancer. Most patients diagnosed at an early stage had ‎good prognoses. However, some individuals with low-grade, low-stage cancers experience ‎recurrence. Prediction of recurrence in those patients is crucial to improve prognosis. CTNNB1 ‎gene mutation is suggested to be associated with endometrial cancer recurrence. CTNNB1 ‎encodes beta-catenin protein.β-catenin is an important mediator in the Wnt/β-catenin signaling ‎pathway. Exon 3 mutations in the CTNNB1 gene activate the canonical Wnt/β-catenin signaling ‎pathway, leading to development of cancer.‎
‎Aim:
The aim of the present study was to study CTNNB1 exon 3 somatic mutations in early stage ‎endometrial cancer in a cohort of Egyptian patients.‎
‎
Patient and ‎Methods:
SUBJECTS: This study was conducted on 40 patients with early stage (stage I&II) ‎endometrioid endometrial carcinoma presented to clinical oncology Department at Alexandria ‎University Hospital. Patients were further divided into two groups; recurrent Group (20 ‎patients with recurrent endometrial cancer who developed metastasis or insitu recurrence) and ‎non recurrent group (20 patients with early stage endometrioid endometrial carcinoma with no ‎recurrence after remission). Formalin fixed paraffin embedded (FFPE) samples were obtained ‎from the Pathology departments at Alexandria University.
Keywords
CTNNB1; exon 3; mutations
Supplementary Files
Statistics
Article View: 73